title: Geographic atrophy in retinal angiomatous proliferation.
abstract: OBJECTIVE
  To describe the occurrence of geographic atrophy in patients with retinal angiomatous proliferation (RAP).
  
  
  METHODS
  Demographics, visual acuity, color fundus photographs, fluorescein and indocyanine green angiograms, and fundus autofluorescence and near-infrared autofluorescence images were reviewed in 53 patients (66 eyes) with RAP.
  
  
  RESULTS
  Of 53 treatment-naive eyes, 19 (36%) had atrophy at baseline. Of 66 eyes, 57 (86%) developed de novo atrophy or enlargement of preexisting areas of atrophy during the follow-up (median, 17 months; range, 3-53 months) after treatment. Areas of atrophy were observed at the site of the RAP (58 of 66 eyes, 88%) of a previously existing pigment epithelial detachment (18 of 44 eyes; 41%) and elsewhere (43 of 66 eyes, 65%). At presentation, RAP was found to be frequently associated with increased autofluorescence at the fovea because of cystoid macular edema (36 of 53 eyes, 68%) and reduced autofluorescence because of hard exudation (38 of 53 eyes, 72%) and intraretinal hemorrhages (32 of 53 eyes, 60%). Background reticular (39%) and homogeneous (36%) autofluorescence were most commonly observed.
  
  
  CONCLUSIONS
  Geographic atrophy occurs frequently in patients with RAP after treatment. This information, if confirmed in other cohorts, would be valuable for the counseling of patients with this disease and for the understanding of the pathogenesis of this condition and its progression after treatment.
authors.affiliation: Department of Ophthalmology, Grampian University Hospitals-NHS Trust, Aberdeen, Scotland, United Kingdom.
authors.forename: Vikki A
authors.initials: VA
authors.lastname: McBain
authors.forename: Reena
authors.initials: R
authors.lastname: Kumari
authors.forename: John
authors.initials: J
authors.lastname: Townend
authors.forename: Noemi
authors.initials: N
authors.lastname: Lois
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D004396:Coloring Agents; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D057092:Geographic Atrophy / Q000150:complications* / Q000175:diagnosis; D006801:Humans; D007208:Indocyanine Green; D017075:Laser Coagulation; D008268:Macular Degeneration / Q000150:complications* / Q000175:diagnosis / Q000628:therapy; D008297:Male; D010778:Photochemotherapy; D015861:Retinal Neovascularization / Q000150:complications* / Q000175:diagnosis / Q000628:therapy; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D004396:Coloring Agents; D007208:Indocyanine Green